AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Imugene limited
Is Pure Hydrogen Driving the Future of Clean Transport?
January 23, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Pure Hydrogen secures order with TOLL Transport for hydrogen fuel cell prime movers.,Expansion into clean transport with collaborations across Asia, Europe, and the US.,Successful projects with Barwon Water, PepsiCo trials, and waste mana...
Imugene’s Preclinical New Mimotope Cancer Vaccine Research Published in Prestigious Journal
May 29, 2020 05:09 PM AEST| By Team Kalkine MediaSummary Imugene's preclinical research associated with mimotope vaccines targeting immune checkpoint inhibitors published in 'Frontiers in Immunology' journal. Research discovered that mimotope peptides when included in Imugene's exclusive immu.....
Catch Sight of Imugene’s Clinical Plan for PD1-Vaxx and CF33 Phase 1 Trials
May 13, 2020 05:12 PM AEST| By Team Kalkine MediaClinical stage Australian immuno-oncology company, Imugene Limited (ASX:IMU) is set to kickstart two clinical trials with B-cell immunotherapy - PD1-Vaxx and oncolytic virotherapy CF33 this year. Recently, Imugene presented presentations on the clini...
Another Notch in Imugene’s Belt, IDMC Confirms Safety of HER-Vaxx Phase 2 Study
May 05, 2020 12:04 PM AEST| By Team Kalkine MediaThe Independent Data Monitoring Committee (IDMC) members have no safety concerns regarding B-cell immunotherapy HER-Vaxx, and biotech player Imugene Limited (ASX:IMU) can continue with its Phase 2 trial without modification, confirmed IDMC chair in a...
Take a Quick Peek into Imugene’s Q1 2020 Operational Highlights
April 28, 2020 12:16 PM AEST| By Team Kalkine MediaAustralia’s clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) will present the clinical plans for the initial Phase 1 trials of its oncolytic virus, Vaxinia (CF33-hNIS) and its PD-1 targeting cancer immunotherapy, PD1-Vaxx at th...
Noteworthy! Imugene Continuing its Planned Activities amid COVID-19 Pandemic
April 14, 2020 11:24 AM AEST| By Team Kalkine MediaAustralian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) is actively implementing risk mitigation and business continuity strategies amidst the global COVID-19 pandemic to continue with its planned activities. The Compa...
Cast an Eye Over Imugene’s Impressive Achievements in 1H FY20
February 28, 2020 02:09 PM AEDT| By Team Kalkine MediaAustralian-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has released another set of robust operational results for the half-year ended 31st December 2019. It was certainly a remarkable half-year for the biotech player,...
Lens through Imugene’s September 2019 Quarterly 4C Report
October 29, 2019 02:31 PM AEDT| By Team Kalkine MediaBiotechnology firm headquartered in Australia, Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology player that develops novel immunotherapies to treat and eradicate cancerous tumours. The company?s unique platform technologies hold the pot...
Advertise your brand on Kalkine Media